Viscoelastic fluid for use in spine and general surgery and other surgery and therapies and method of using same

• US 5,156,839 A
• Filed: 06/14/1990
• Issued: 10/20/1992
• Est. Priority Date: 05/04/1987
• Status: Expired due to Term

• Current Assignee: Fziomed, Inc.
• Original Assignee: MDR Group LLC
• Inventors: Allen, Mark D., Pennell, Phillip E., Blackmore, John M.
• Primary Examiner(s): Waddell, Frederick E.
• Assistant Examiner(s): Fay, Zohreh A.
• Application Number:
  US07/538,232
• Time in Patent Office: 859 Days
• Field of Search: 424/78, 424/83, 514/57, 514/912, 514/915
• US Class Current: 424/78.37
• CPC Class Codes: A61F 9/007 Methods or devices for eye surgery
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61L 27/26 Mixtures of macromolecular compounds
• CPC Class Codes: C08L 71/02 Polyalkylene oxides

Abstract

This invention relates to an improved viscoelastic fluid or gel for use in general surgery and also more specifically in spine and neurosurgery and also in surgery dealing with reproductive organs. The invention encompasses the method of delivering to a surgical wound an implant composition having up to about a 21/2% by weight of carboxymethylcellulose (CMC) and at least about a 0.5% by weight polyethylene oxide (PEO) in a physiologically acceptable mixture.

Claims

1. A method of preventing scar formation in sterile parts of the body during and following surgery comprising the step of:

delivering to a wound an implant composition having up to about 21/2% by weight of carboxymethylcellulose (CMC) and up to about 0.5% by weight of polyethylene oxide (PEO) in a physiologically acceptable mixture.

2. The method of claim 1 wherein prior to delivery, the implant composition of about 2.5% by weight of carboxymethylcellulose (CMC) and about 0.5% by weight of polyethylene oxide (PEO) in a physiologically acceptable mixture is crosslinked in order to control retention at the wound by including about 0.25% by weight of dimethyl urea a crosslinking agent and about 0.025% by weight ammonium chloride as a catalyst.

3. The method of claim 1 including the step of:

allowing the delivered implant composition to be absorbed into the wound.

4. The method of claim 1 including the step of:

preparatory to the delivering step, cutting through the skin and topically applying to the subcutaneous tissue prior to surgical dissection a topical composition having upto about 1% by weight of carboxymethylcellulose(CMC) and upto about 0.05% by weight of polyethylene oxide (PEO) in a physiologically acceptable mixture.

5. The method of claim 4 including the step of:

removing the topical composition before delivering the implant composition.

6. A method of preventing scar formation in sterile parts thereof during and following the performance of surgical procedures on reproductive organs of a mammal comprising the step of:

delivering to a wound an implant composition having up to about 21/2% by weight of carboxymethylcellulose (CMC) and up to about 0.5% by weight of polyethylene oxide (PEO) in a physiologically acceptable mixture.

7. The method of claim 6 wherein prior to delivery, the implant composition of about 2.5% by weight of carboxymethylcellulose (CMC) and about 0.5% by weight of polyethylene oxide (PEO) in a physiologically acceptable mixture is crosslinked in order to control retention at the wound by including about 0.25% by weight of dimethyl urea a crosslinking agent and about 0.025% by weight ammonium chloride as a catalyst.

8. The method of claim 6 including the step of:

allowing the delivered implant composition to be absorbed into the wound.

9. The method of claim 6 including the step of:

preparatory to the delivering step, cutting through the skin and topically applying to the subcutaneous tissue prior to surgical dissection a topical composition having upto about 1% by weight of carboxymethylcellulose(CMC) and upto about 0.05% by weight of polyethylene oxide (PEO) in a physiologically acceptable mixture.

10. The method of claim 9 including the step of:

removing the optical composition before delivering the implant composition.

11. The method of claim 6 including the step of:

preparatory to the delivering step, surgically accessing the reproductive organs of a mammal and performing modifications to the reproductive organs at the wound created by the surgical accessing step.

12. A method of preventing scar formation in sterile parts of the body during and following spine surgery comprising the step of:

delivering to a wound an implant composition having up to about 21/2% by weight of carboxymethylcellulose (CMC) and up to about 0.5% by weight polyethylene oxide (PEO) in a physiologically acceptable mixture.

13. The method of claim 12 wherein prior to delivery, the implant composition of about 2.5% by weight of carboxymethylcellulose (CMC) and about 0.5% by weight of polyethylene oxide (PEO) in a physiologically acceptable mixture is crosslinked in order to control retention at the wound by including about 0.25% by weight of dimethyl urea a crosslinking agent and about 0.025% by weight ammonium chloride as a catalyst.

14. The method of claim 12 including the step of:

allowing the delivered implant composition to be absorbed into the wound.

15. The method of claim 12 including the step of:

preparatory to the delivering step, cutting through the skin and topically applying to the subcutaneous tissue prior to surgical dissection a topical composition having upto about 1% by weight of carboxymethylcellulose(CMC) and upto about 0.05% by weight of polyethylene oxide (PEO) in a physiologically acceptable mixture.

16. The method of claim 15 including the step of:

removing the topical composition before delivering the implant composition.

17. The method of claim 12 including the step of:

preparatory to the delivering step, surgically accessing the spine and performing modifications to the spine at the wound created.